Key clinical point: Intensive postoperative chemotherapy and focal radiation therapy may improve event-free survival for patients with atypical teratoid/rhabdoid tumors.

Major finding: The treatment protocol was associated with a significantly lower risk of event-free survival events than that of historical therapies (hazard ratio, 0.43; P less than .0005).

Study details: ACNS0333 is a nonrandomized, phase 3 trial of 65 patients with atypical teratoid/rhabdoid tumors.

Disclosures: The study was funded by the Children’s Oncology Group, the National Institutes of Health, the St. Baldrick’s Foundation, the Canadian Cancer Society, and the Children’s of Alabama Kaul Pediatric Research Institute. The investigators disclosed relationships with Novartis, AstraZeneca, and Merck Sharp & Dohme.